Developed for addiction counselors, this course reviews the use of buprenorphine in office-based treatment of opioid addiction. It examines legislative changes that permit office-based buprenorphine treatment, including physician and counseling recommendations. It addresses the science of addiction and the ways in which buprenorphine treatment is part of that endeavor. The course reviews opioids and their effects, and the effects, efficacy, and safety of buprenorphine. It examines patient selection issues, diagnostic evaluations, and appropriateness and contraindications for office-based treatment. It addresses counseling-related issues such as patient confidentiality, recovery and sobriety, pharmacotherapy, 12-Step program issues, readiness for discontinuation evaluations, and responding to problematic patient behaviors.
Michael McCann, M.A., Associate Director, Matrix Institute; Jeanne Obert, M.F.T., M.S.M., Executive Director, Matrix Institute; Walter Ling, M.D., Director, UCLA Integrated Substance Abuse Programs.
The Matrix Institute on Addictions. A leader in research-based practices, the Matrix Institute on Addictions is committed to improving the lives of individuals and families affected by alcohol and other drug use through (1) treatment services in the greater Los Angeles area; (2) national and regional training and education; and (3) research and grants with NIDA and CSAT, and in collaboration with the UCLA Integrated Substance Abuse Programs which coordinates substance abuse research and treatment under authority of the UCLA Neuropsychiatric Institute & Hospital.
This course is sponsored by the Central East Addiction Technology Transfer Center and was developed with funding from CSAT.
This activity has been approved by the National Association for Alcoholism and Drug Abuse Counselors for up to 3 credit hours under the Danya Institute's Provider Number 309.
Time: 3 hours
By the end of this course, you will be able to:
- Describe important changes in Federal legislation that permit office-based treatment of opioid addiction using buprenorphine
- Understand and describe ways in which buprenorphine has been shown to be a safe and effective medication to treat opioid addiction
- Conduct assessments to determine if a patient is opioid addicted and suitable for buprenorphine treatment, and if the office is the optimal site for treatment; help patients who want to stop using buprenorphine by conducting readiness to discontinue evaluations, using the Tapering Readiness Inventory
- Understand Federal confidentiality regulations that protect the confidentiality of patients receiving treatment, and understand HIPAA regulations that specify protections for personal health information
- Teach patients to work with and not against pharmacotherapy, use tools designed to enhance patients' motivation for change, and conduct biopsychosocial needs assessments
- Dispel myths about buprenorphine and provide accurate information about the use of buprenorphine for opioid-addiction treatment; educate patients about the official position of the 12-Step programs regarding the use of prescribed medication, describe the benefits of the 12-Step programs, and promote the use of these self-help programs
- Manage problematic patient problems, including manipulation, blurring of boundaries, threats to safety and security, intoxication, loitering, and drug dealing